Understanding the European Market

The Challenge

The Challenge

A mid-sized pharmaceutical company was looking to enter the European market through a compassionate use/early access pathway but lacked an understanding of the requirements specific to each country that would lead to broad access and reimbursement for their product across Europe.

The IP Solution

The IP Solution

To gain in-depth knowledge of the European market landscape as it related to compassionate use/early access, we employed our team of European experts to conduct primary and secondary market research.

With our deep understanding of the intricacies of the market in conjunction with our knowledge of the EMA and EU pharmaceutical legislation options, we developed a plan which outlining various pathways to early access across the EU5 and United Kingdom, including specific insights into marketing authorization pricing and reimbursement strategies for each country.

The Result

The Results

IP’s detailed strategy and recommendations enabled the company to provide patients across European Markets access to their product as quickly as possible.

Related Case Studies

Healthcare Policy Changes Interpreted in Real-Time

A European-based pharmaceutical company with several products in the US market was under pressure to interpret and respond to rapidly changing US healthcare policies which could potentially impact access for their portfolio of oncology products.

A Comprehensive Launch Strategy Leads to Broad Access

A biopharmaceutical company was in the midst of bringing its first product to market with breakthrough therapy designation. The PDUFA date was fast approaching, and their small team needed guidance to steer them through the complicated access and reimbursement landscape.

Insight Into a New Therapeutic Landscape

A precision therapies-focused biopharmaceutical company was bringing their second product to market. In order to support product access at the provider level and drive market share and utilization, it was critical they understood the oncology clinical pathway landscape within two distinct therapeutic classes.